Reason for request
Indication extension
Summary of opinion
Favourable opinion for reimbursement in the following indication: “KEYTRUDA, in combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), in the treatment of FIGO 2014 Stage III (extension onto the pelvic wall or lower one-third of the vagina and/or causing hydronephrosis or non-functioning kidney) to IVA (involvement of the mucosa of bladder/rectum -adjacent pelvic organ spread-) with or without involvement of the pelvic and/or para-aortic lymph nodes) locally advanced cervical cancer in adults who have not received prior definitive therapy.”
Clinical Benefit
| Substantial |
The Committee deems that the clinical benefit of KEYTRUDA (pembrolizumab), in combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), is substantial in the indication: “in combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), in the treatment of FIGO 2014 Stage III (extension onto the pelvic wall or lower one-third of the vagina and/or causing hydronephrosis or non-functioning kidney) to IVA (involvement of the mucosa of bladder/rectum -adjacent pelvic organ spread-) with or without involvement of the pelvic and/or para-aortic lymph nodes) locally advanced cervical cancer in adults who have not received prior definitive therapy.”
|
Clinical Added Value
| moderate |
Considering:
- demonstration in a randomised, double-blind, phase 3 study (KN-A18 trial, including 56.7% FIGO 2014 stage III - IVA patients) of the superiority of pembrolizumab compared to chemoradiotherapy, for the treatment of FIGO stage IB2-IIB and III - IVA locally advanced cervical cancer in adults who have not received prior definitive therapy, in terms of:
- progression-free survival with an HR = 0.70 (95% CI = [0.55; 0.89]; p = 0.002 < the predefined threshold of 0.0172), 7% patients progressed or died in the experimental group versus 29.0% patients in the control group. The median PFS was not reached in either of the two groups.
- overall survival with an HR = 0.67 (95% CI = [0.50; 0.90]; p = 0.0040 < 0.01026), 2% deaths in the experimental group versus 20.5% patients in the control group. The median OS was not reached in either of the two groups.
And despite:
- the absence of any formal conclusion that can be drawn based on the quality of life findings;
- a safety profile deemed to be acceptable compared to chemoradiotherapy but marked by an excess toxicity with grade ≥ 3 AEs reported in 78.3% of patients in the pembrolizumab group and 70.0% of patients in the placebo group). In addition, 20.6% of patients in the pembrolizumab group and 14.9% of patients in the placebo group had an AE resulting in definitive discontinuation of pembrolizumab treatment.
The Committee deems that KEYTRUDA (pembrolizumab) 25 mg/ml, concentrate for solution for infusion, in combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), provides a moderate clinical added value (CAV III) compared to chemoradiotherapy.
|
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
9KVQj5mupMNjtxxA